Article Sidebar
Published:
Feb 2, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Upregulation of AKAP12 by demethylation inhibits proliferation and increases chem osensitivity to adriamycin in leukemic cells
Abstract
Purpose: To elucidate the role of AKAP12 in leukemia cells.
Methods: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB) were employed to determine the expression of AKAP12 in leukocyte cell lines, while 5-azacytidine was used to treat the cells, followed by assessment of the expression of AKAP12. After constructing the overexpressing vector pc-AKAP12 and transfecting it into cells or treating the cells with 5-azacytidine, cell counting kit-8 assay (CCK-8) was used to determine cell proliferation. Cloning ability of the cells was evaluated by colony formation assay. Furthermore, flow cytometry was employed to measure the degrees of cell cycle and cell apoptosis. The effect of AKAP12 on PI3K/AKT were determined by western blot.
Results: The results showed that AKAP12 was lowly expressed in lymphocytic leukemia cell lines (p < 0.001), but was reversed by 5-azacytidine. Transfection of AKAP12 or 5-azacytidine treatment increased the expression of AKAP12 in the cells (p > 0.001), inhibited leukemia cell proliferation and clonality, and arrested cell cycle in G1 phase as well as induced apoptosis. In addition, PI3K/AKT signaling pathway was inhibited by AKAP12.
Conclusion: AKAP12 is lowly expressed in leukemia cells, and may also play a role in inhibiting leukemia progression by suppressing the activity of PI3K/AKT pathway.Thus, targeting AKAP12 mght be a potential strategy in the management of lukemia.
